The appeal of BaEV envelope proteins lies in the receptors they exploit. BaEV Env enters cells by engaging ASCT2, a sodium-dependent neutral amino acid transporter, and can also use the related transporter ASCT1 as an auxiliary receptor. Both transporters are abundantly expressed on primary human hematopoietic cell types, which explains why vectors pseudotyped with BaEV Env consistently outperform those coated with the gibbon ape leukemia virus (GaLV) or feline RD114 envelopes that are used in today’s approved CAR therapies. BaEV-pseudotyped lentiviral, α-retroviral, and γ-retroviral particles have all demonstrated highly efficient gene transfer into primary human blood cells, making the envelope a sought-after tool for cell therapeutic strategies that aim to modify hematopoietic stem and progenitor cells, T cells, B cells, and NK cells.

There has, however, been a catch. The fusogenicity that makes BaEV Env such an effective entry machine also makes it destructive to producer cells. During γ-retroviral particle maturation, the viral protease cleaves the so-called R-peptide from the cytoplasmic domain of the envelope, a processing step that activates the membrane-fusion capacity of the protein. In stable packaging cells, where envelope is constitutively expressed at the cell surface, this fusion activity causes adjacent cells to merge into giant multinucleated syncytia. Previous attempts to establish stable BaEV Env producer lines in 293T cells were forced to knock out the cognate receptors ASCT1 and ASCT2 to prevent the cells from fusing themselves to death — a cumbersome and time-consuming genetic engineering step. Env variants with a deleted R-peptide, such as BaEVΔR, are constitutively fusogenic and even more toxic in this setting.

The new study’s strategy hinged on an alternative envelope variant termed BaEV-TR. The TR designation refers to a chimeric design first pioneered with foamy virus envelopes in 1997, in which the entire cytoplasmic tail of the heterologous Env is replaced with the homologous domain of murine leukemia virus (MLV). This substitution accomplishes two things at once. First, it places the MLV R-peptide at the cytoplasmic end of the chimeric protein, allowing efficient processing by the MLV protease during particle assembly. Second, the MLV R-peptide mediates direct interaction with the Gag core proteins, promoting efficient recruitment and incorporation of the envelope during budding. Critically, previous work had suggested that BaEV-TR, unlike the wild-type and ΔR variants, does not trigger visible syncytia formation in transiently transfected 293T cells.

The researchers, led by Angelina Hallik, Mona Pißarreck, and Jörn Stitz, first reconfirmed this crucial safety property in two human cell lines. They transiently co-transfected 293T embryonic kidney cells and HT1080 fibrosarcoma cells with an enhanced green fluorescent protein reporter plasmid together with constructs encoding either BaEV-TR, the highly fusogenic BaEVΔR as a positive control, or an empty vector as a negative control. Over four days of observation, cells expressing BaEV-TR showed no syncytia whatsoever in either cell line, while BaEVΔR-expressing 293T cells fused extensively as expected. Interestingly, HT1080 cells expressing BaEVΔR formed syncytia only rarely, a difference the authors interpret as evidence of comparatively lower ASCT receptor density on the fibrosarcoma cells, though quantitative receptor measurement would be needed to confirm this hypothesis.

This reduced receptor expression made HT1080 an attractive host for stable producer cell development. Lower receptor density offers two theoretical advantages: envelope proteins on the cell surface should be less likely to interact prematurely with their own receptors during expression and intracellular trafficking, leaving more Env available for incorporation into budding particles; and receptor interference — the resistance to superinfection that develops when a cell’s receptors are occupied by expressed envelope — should minimize the risk that producer cells are re-transduced by their own vectors. Using Sleeping Beauty transposon vector technology, the team introduced the BaEV-TR envelope construct, an MLV packaging construct, a GFP-encoding transfer vector, and the SB100X transposase into HT1080 cells. After three weeks of escalating selection with puromycin, hygromycin B, and G418, they obtained a stable polyclonal producer line named HT/BaEV-TR.

Biochemical verification followed. The team collected cell-free supernatants from the producer line, concentrated the vector particles by centrifugation, and probed them by Western blot with antibodies specific for the extracellular domain of BaEV Env and for the MLV p30 capsid protein. Both proteins were readily detected in the particles harvested from HT/BaEV-TR but were absent from supernatants of unmodified HT1080 cells, confirming that the chimeric envelope had been successfully incorporated into MLV-derived vector particles.

The functional test was the decisive one. Cell-free vector preparations from different passages, harvested at roughly weekly intervals over several months, were used to transduce a panel of human target cell lines, with gene transfer quantified by flow cytometric detection of GFP-positive cells. The results demonstrated both potency and durability. In naive 293T target cells, the vectors achieved a mean titer of 3.3 × 10⁶ transducing units per milliliter — a figure exceeding 3.0 × 10⁶ TU/mL across three independent experiments. In HT1080 targets, the mean titer was 4.8 × 10⁵ TU/mL, consistent with the assumed lower receptor density and slower proliferation rate of these cells. Most importantly for therapeutic applications, the hematopoietic cell lines were transduced efficiently: pro-monocytic U937 cells yielded a mean titer of 8.0 × 10⁵ TU/mL, K562 lymphoblasts 6.1 × 10⁵ TU/mL, Jurkat T lymphoblasts 5.2 × 10⁵ TU/mL, and acute promyelocytic leukemia NB4 cells 1.0 × 10⁵ TU/mL. The repeatable high titers across passages indicated stable, long-term productivity of the cell line.

The implications extend beyond this single producer line. Because MLV-based γ-retroviral vectors can only transduce dividing cells, target cell proliferation and possibly intracellular retroviral restriction factors influence the observed titers, and the authors note that validation in primary hematopoietic cells will be required in future studies — the present work used only established cell lines. Nevertheless, the proof of concept is clear: the BaEV-TR envelope variant permits the establishment of stable, non-fusogenic, high-titer producer cells without any need to knock out the ASCT1 or ASCT2 receptors, removing the most burdensome step in generating BaEV-enveloped packaging lines. The study also validates HT1080 cells as a viable alternative host to the 293T derivatives that dominate the field, potentially offering favorable production characteristics.

For the gene and cell therapy field, the prospect of continuously producing BaEV-pseudotyped γ-retroviral vectors from stable cell lines could substantially simplify manufacturing. Stable producer cells eliminate the variability inherent in transient transfection-based production, support scalable and reproducible vector supply, and — as other recent work with suspension packaging lines has shown — can enable bioreactor-based manufacturing. If subsequent studies confirm that vectors from HT/BaEV-TR-like lines deliver the same outstanding gene transfer into primary human hematopoietic stem, T, B, and NK cells that transiently produced BaEV vectors have already demonstrated, the engineered baboon envelope variant could move from a laboratory curiosity to a foundation for the next generation of cell therapeutic manufacturing platforms.

Subject of Research: Stable human packaging cell lines for BaEV-TR pseudotyped γ-retroviral vector production

Article Title: High-titer human packaging cells producing γ-retroviral vectors pseudotyped with engineered baboon endogenous retrovirus (BaEV) envelope proteins

Article References: Hallik, A., Pißarreck, M., Grummel, M. J., van Heuvel, Y., & Stitz, J. (2026). High-titer human packaging cells producing γ-retroviral vectors pseudotyped with engineered baboon endogenous retrovirus (BaEV) envelope proteins. Frontiers in Molecular Medicine, 6, Article 1888550. https://doi.org/10.3389/fmmed.2026.1888550

Image Credits: AI Generated

DOI: 10.3389/fmmed.2026.1888550

Keywords: baboon endogenous retrovirus, BaEV-TR envelope, γ-retroviral vectors, packaging cell line, gene therapy, HT1080 cells, murine leukemia virus, pseudotyping, syncytia formation, ASCT2 receptor, CAR cell therapy, viral vector manufacturing